✦ LIBER ✦

Combination of targeted agents in metastatic renal cell carcinoma : A path forward or a dead-end street?

✍ Scribed by M. Dror Michaelson

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maximising the duration of disease contr

✍ C. Porta, G. Tortora, C. Linassier, K. Papazisis, A. Awada, D. Berthold, J. P. M 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 376 KB

P040 Antiangiogenic targeted agents impr

✍ Iacovelli, R.; Verzoni, E.; Palazzo, A.; Grassi, P.; Testa, I.; Cortesi, E.; Pro 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 68 KB

4533 POSTER Combination of gemcitabine a

✍ Roubaud, G.; Dilhuydy, M.S.; Pasticier, G.; de Clermont, H.; Smith, D.; Ravaud, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 80 KB

A phase 1b clinical trial of the multi-t

✍ Molina, Ana M.; Hutson, Thomas E.; Larkin, James; Gold, Anne M.; Wood, Karen; Ca 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 395 KB

Carbonic anhydrase IX as a potential bio

✍ Choueiri, Toni K.; Cheng, Suchun; Qu, Angela Q.; Pastorek, Jaromir; Atkins, Mich 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 353 KB

883 POSTER Phase I trial of sorafenib (B

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB